Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Elizabeth Smyth MD
Elizabeth Smyth MD Advisory Board
David Henry MD
David Henry MD Advisory Board
Alexander van Akkooi MD, PhD, FRACS
Alexander C. J. van Akkooi MD, PhD, FRACS Associate Editor
See All Experts
featured
Published in Oncology

Expert Opinion / Commentary · December 15, 2017

2017 Top Stories in Oncology: Multiple Myeloma

Rafael Fonseca MD

 

 Save  Recommend
 Share

Additional Info

  1. Fan F, Zhao W, Liu J, et al. Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma. Paper presented at: 2017 American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL. Abstract LBA3001.
  2. Berdeja JG, Lin Y, Raje NS, et al. Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy. Paper presented at: American Society of Hematology 2017 Annual Meeting and Exposition; December 9-11, 2017; Atlanta, GA. Abstract 740.

Disclosure statements are available on the authors' profiles:

Rafael Fonseca MD

Further Reading

Most Read This Week

Recently Updated